AEterna Zentaris Inc. (AEZS)

[TwoPack]

Commenting on the compound, Dr. Richard Sachse, the Company's Chief Medical and Chief Scientific Officer, stated, “We believe that zoptarelin doxorubicin has the potential to become the first FDA approved medical therapy for advanced, recurrent endometrial cancer. This could result in its rapid adoption as a novel core therapy for treatment and management of advanced, recurrent endometrial cancer. Our hope is that the compound will improve and extend the quality of the lives of patients with this devastating disease.”
AEZS news 08-11-2015
'Expect' sounds more concrete than 'believe', 'could' and 'hope', doesn't it?
So as I said in one of my last posts the sentence 'expect...' gives a line of possibly succeccful working with Zopta-Doxo at Southwestern. Barely enough to talk about successful interim results of the trial as a whole.
Just posted picture needed for discussion here. Personally I agree with you 'expect...' not to be that great leaked info :D but nevertheless a puzzle to the whole picture we have to build together.

Didn't understand this:
Plus what about the CRL from earlier this year? That was supposed to be the next newest and best thing ever.
What you mean?